13:00
May 11

Cannabotech raised NIS 1.2 million in a public offering

11:30
May 10

Together achieved an export permission from Germany to UK

14:00
January 20

Panaxia reports the first export of cannabis tablets to France as part of the pilot in which it participates and is expected to last about two years. The tablets were delivered to France free of charge.

13:00
January 22

Togther reports that the Securities Authority has initiated administrative enforcement proceedings against it in respect of its previous reports from 2018 and 2019 regarding business relations with China.

About

Cannabis Capital is an independent magazine, focusing on the Israeli cannabis and psychedelic industries.
The magazine brings to its readers real-time news, investment opportunities and in-depth analysis.
Cannabis Capital is the content branch of Nishot Strategy and Analysis.

Nishot Strategy and Analysis

Nishot is an Israeli-based financial advisory firm, focusing on the Israeli cannabis and psychedelics sector. Nishot services include: Unbiased buy-side analysis for investors, M&A strategy and due-diligence services, and business consultancy for investors and companies in the Israeli market.
In addition, Nishot serves as an advisor for an Israeli mutual fund that invests in cannabis companies.

Shiry Eden

Ms. Eden is the founder and CEO of Nishot and Cannabis Capital. Eden is an analyst and a strategic consultant with over 20 years of experience.
Prior to the establishment of Nishot , she has advised dozens of public traded companies in Israel, and developed vast understanding of the Israeli capital market.
Before that, she served as a corporate communications manager in the second largest investment house in Israel, media advisor for the Minister of Defense, and an economist in the Budget Department of the Ministry of Defense (rank captain). Eden holds a BA in Economics and Communications from the Hebrew University and an MBA from Tel Aviv University.

** The contents of the website are not a recommendation or advice for securities transactions. The information provided on the site is not a substitute for personal counseling that is considerate and tailored to the needs of each person performed by a qualified counselor. Also, the services provided on the site do not contain any recommendation or opinion and it does not replace the independent judgment of the readers. The site staff is not responsible for any losses that may be incurred by a securities investor.

* The content on the site does not constitute a professional opinion, recommendation, substitute for consulting a specialist or receiving medical advice. Cannabis is a dangerous drug, as defined in the Dangerous Drugs Ordinance, for all that that implies.
Cannabis Capital does not encourage or recommend consuming any substance and will not be responsible for any such use.